Table 3 Treatment-emergent adverse event (TEAEs) occurring at weeks 4, 8 and 12
| Â | Week 4 | Week 8 | Week 12 |
|---|---|---|---|
Patients n | 60 | 58 | 53 |
Patients with ≥ 1 TEAE | 1 (1.7%) | 2 (3.4%) | 3 (5.7%) |
•Injection site erythema | 1 (1.7%) | 1 (1.7%) | 1 (1.9%) |
•Dizziness | - | 1 (1.7%) | - |
•Abdominal pain | - | - | 1 (1.9%) |
•Neck pain and somnolence | - | - | 1 (1.0%) |
Discontinuation due to TEAEs | - | - | - |
Discontinuation due to ineffectiveness | - | - | - |